Ohio pharmacy board publishes GLP-1 compounding guidance

Ohio's Board of Pharmacy published guidance in July 2025 that tightens rules on compounded GLP-1 medications sold in the state. The guidance treats semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) and tirzepatide (used in Mounjaro and Zepbound) as no longer eligible to be compounded as copies of the approved brand drugs ^[1]. The board also expressly prohibited two investigational compounds, retatrutide and cagrilintide, from being compounded at all ^[1]. In addition, the guidance requires that pharmacies buy the active pharmaceutical ingredients for any compounding from a distributor licensed in Ohio ^[1].

The guidance did not create new law on its own. According to a legal analysis of state GLP-1 rules, Ohio's position largely restates existing federal law rather than adding a stricter substantive standard ^[1]. Under federal rules, compounding pharmacies could legally make copies of semaglutide and tirzepatide only while the FDA listed those drugs as being in shortage. Once the FDA resolved those shortages, that legal pathway closed, and the FDA has since reinforced the point through guidance on what counts as compounding "essentially a copy" of an approved drug ^[1].

What sets Ohio apart, according to the analysis, is not the rule itself but how the board has enforced it. Ohio's pharmacy board reports that it has summarily suspended more than thirty clinics and medical spas since the start of 2025 ^[1]. The analysis groups Ohio with Washington state as "enforcers" — states where board guidance mirrors federal law but where the boards have shown they are willing to act against pharmacies and clinics that don't comply ^[1]. That puts Ohio in a different category from states like Texas and Florida, which have no GLP-1-specific board position and rely on general compounding frameworks ^[1], and different again from California, described as the only state to have written a compounding standard into law that is stricter than the federal baseline ^[1].

Why it matters for patients

For Ohio patients who have been getting compounded semaglutide or tirzepatide from a local pharmacy, clinic, or medical spa, this guidance signals that such products face a higher chance of being pulled from the market or the provider being disciplined. The board's track record of more than thirty suspensions since January 2025 suggests enforcement is not just on paper ^[1]. Patients relying on compounded versions of these drugs, including through telehealth, may find that Ohio providers are less able to offer them going forward, particularly if a product cannot show a documented, clinically significant reason for differing from the FDA-approved brand ^[1].

The ban on retatrutide and cagrilintide also matters for anyone who may have been offered these substances through a compounding pharmacy or clinic. Neither has an FDA-approved reference product, and the analysis notes that investigational GLP-1-related molecules like these are being expressly prohibited in some states ^[1]. Patients considering any compounded GLP-1 product may want to be aware that its legal status can vary significantly depending on the state where it is dispensed, and that guidance documents, while not carrying the same legal force as a formal regulation, still appear to drive real enforcement action in Ohio ^[1].

What happens next

The legal analysis suggests that Ohio's trajectory will likely continue to track federal policy on GLP-1 compounding, which has been tightening even as federal rules on other peptides have been loosening ^[1]. The analysis notes that most states without their own GLP-1-specific rules will follow whatever federal regulators decide, while enforcement-focused states such as Ohio and Washington are expected to remain higher-risk jurisdictions for compounders regardless of where federal substantive rules land, because their risk stems from the boards' demonstrated willingness to pursue disciplinary action ^[1]. No specific dated milestones for further Ohio board action were included in the available reporting.